Claims for Patent: 7,700,748

Summary for Patent: 7,700,748

Title:	VMGLOM gene and its mutations causing disorders with a vascular component
Abstract:	The present invention relates to genes responsible for disorders with a vascular component, the identification of mutations in said genes and the detection of their sequences as well as methods for detection and treatment for disorders with a vascular component. This invention further relates to proteins encoded by said genes and their applications.
Inventor(s):	Vikkula; Miikka (Kraainem, BE)
Assignee:	Universite Catholique de Louvain (Louvain-la-Neuve, BE)
Application Number:	10/204,254
Patent Claims:	1. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule encoding a human polypeptide having the sequence of SEQ ID NO 2, (b) a nucleic acid molecule encoding a human polypeptide having the amino acid sequence of amino acid position 405 to 594 in SEQ ID NO 2, (c) a nucleic acid molecule encoding a human polypeptide consisting of the amino acid sequence of SEQ ID NO 4, (d) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO 1 or 3, and (e) a nucleic acid molecule consisting of the 85 bp nucleotide sequence of position 1253 to 1337 in SEQ ID NO 1, (f) a modified SEQ ID NO: 1 having a mutation selected from the group consisting of deletion of 2 nucleotides, positions 31-32; insertion of a G, position 107; substitution of a C by an A, position 108; deletion of 5 nucleotides, positions 157-161; insertion of an A, position 423; deletion of 4 nucleotides, positions 554+556-558; deletion of the 5th nucleotide (G) in the splice-site consensus in intron 5 (5' end of intron); deletion of 4 nucleotides, positions 842-845; deletion of 3 nucleotides, positions 1179-1181; deletion of a T, position 1355; deletion of 4 nucleotides, positions 1470-1473; substitution of a C by a G, position 1547; and deletion of GT, positions 1711-1712, wherein numbering of said mutations refers to the nucleotide numbering as used in SEQ ID NO: 1, where +1 is the A of the ATG codon at positions 39 to 41, and (g) a nucleic acid molecule comprising the nucleotide sequence set forth by SEQ ID NO: 143 with a deletion of the TA at position 3800-3801 and the full length complement thereof. 2. A molecule comprising the isolated nucleic acid according to claim 1 wherein said molecule is incorporated into a diagnostic kit. 3. A composition comprising the molecule according to claim 2. 4. A method for detecting the presence of mutations of claim 1 associated with venous malformations of glomus cells in a nucleic acid sequence comprising obtaining a sample containing nucleic acids, and determining the presence of mutations in a nucleic acid sequence wherein the nucleic acid sequence is a nucleic acid sequence according to claim 1. 5. An isolated DNA construct comprising a nucleic acid consisting of the nucleic acid according to claim 1. 6. An isolated host cell transformed in vitro with a DNA construct according to claim 5.

Details for Patent 7,700,748

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-02-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-02-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-02-16